Bioorthogonal fluorogenic probes optimize fluorescence and enable STED imaging and drug release applications.
A unique class of bioorthogonal fluorogenic probes, based on difluoroboronated tetrazine ( Tz-BFs ), has been developed. These probes are the smallest tetrazine-based fluorescent structures and exhibit a high fluorescence turn-on ratio (up to 582-fold) following the inverse electron-demand Diels-Alder reaction. By engineering π-conjugated systems and using push-pull groups, their fluorescence emission can be tuned across blue to yellow (440 to 570 nanometers). They offer no-wash fluorogenic behavior, excellent cell permeability, rapid reaction kinetics, and high photostability, ideal for real-time biomolecule tracking, suborganelle bioorthogonal imaging, and metabolic labeling. In addition, they enable stimulated emission depletion (STED) microscopy for subdiffraction resolution imaging and have click-to-release functionality for simultaneous fluorescence activation and therapeutic agent release, such as TCO ( trans -cyclooctene)–DOX (doxorubicin). These probes provide broad potential for advanced imaging and drug delivery applications.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: